- Home
- CLRO vs MBRX Comparison
CLRO vs MBRX Comparison
Compare CLRO & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLRO | MBRX |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 10.1M |
| IPO Year | 2018 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CLRO | MBRX |
|---|---|---|
| Price | $5.00 | $0.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 686.9K | ★ 1.1M |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $46,067,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.59 | N/A |
| 52 Week Low | $2.71 | $0.16 |
| 52 Week High | $16.50 | $7.98 |
Technical Indicators
Market Signals| Indicator | CLRO | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.79 | 35.94 |
| Support Level | $4.47 | $0.50 |
| Resistance Level | $6.42 | $0.67 |
| Average True Range (ATR) | 0.60 | 0.09 |
| MACD | 0.14 | -0.00 |
| Stochastic Oscillator | 69.55 | 3.96 |
Price Performance
Historical ComparisonAbout CLRO ClearOne Inc. (DE)
ClearOne Inc is currently engaged in activities that consist solely of fulfilling warranty and technical support obligations on legacy products, evaluating potential Strategic Transactions, managing and liquidating remaining assets of the company's legacy operating business, collecting accounts receivable and recovering prepaid assets, satisfying outstanding liabilities, and maintaining public-company compliance.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.